The present invention relates to novel crystalline forms of (R)-2-[[[3-methyl-4(2,2,2- trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lH-benzimidazole (Formula 1), to processes for their preparation, to pharmaceutical compositions comprising the same and to the use of such crystalline forms for the treatment of gastrointestinal (GI) disorders.La présente invention concerne des nouvelles formes cristallines de (R)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lH-benzimidazole (Formule 1), des procédés pour leur préparation, des compositions pharmaceutiques les comprenant et l'utilisation de telles formes cristallines pour le traitement de troubles gastro-intestinaux (GI).